Additionally, our data show a lack of response in individuals with prediabetes, which is consistent with the observation that a 4-week oral administration of butyrate altered metabolism and insulin sensitivity in lean individuals but not in individuals with obesity and IR [117]. Here, INS is linked to obesity disorder.